The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment?

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children. Several studies suggest that the improvement of oxidative stress is suggested as a possible therapeutic strategy for pediatric nonalcoholic steatohepatitis. We performed a randomized, double-blind placebo-controlled trial to test the potential efficacy, assessed by improvement of oxidative stress parameters and liver ultrasound, and tolerability of a mixture of vitamin E and hydroxytyrosol (HXT) in adolescents with biopsy-proven NAFLD. Four hundred forty consecutive patients were screened, 80 of these with biopsy-proven NAFLD were enrolled. Forty patients received an oral dose of HXT and vitamin E and 40 children received the capsules of placebo for 4 months. Seventy patients completed the study. Patients in the treatment arm showed a decrease of insulin resistance (IR), triglyceride levels, oxidative stress parameters, and steatosis grade. Noteworthy, the steatosis improvement correlates with the levels of advanced glycation end products and carbonylated proteins. The HXT and vitamin E treatment improved the main oxidative stress parameters, IR, and steatosis in children with NAFLD. The use of two natural molecules that may have antioxidant effects seems a promising strategy that could be easily diet integrated to improve NAFLD-related liver damage in children.

• Authors: Valerio Nobili, Anna Alisi, Antonella Mosca, Annalisa Crudele, Salvatore Zaffina, Marcella Denaro, Antonella Smeriglio, Domenico Trombetta
• Journal: Antioxidants & redox signaling (Antioxid Redox Signal) Vol. 31 Issue 2 Pg. 127-133 (07 10 2019) ISSN: 1557-7716 [Electronic] United States
• PMID: 30588836 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Glycation End Products, Advanced
• 3,4-dihydroxyphenylethanol
• Vitamin E
• Phenylethyl Alcohol

Topics

• Administration, Oral
• Adolescent
• Child
• Double-Blind Method
• Female
• Glycation End Products, Advanced (drug effects, metabolism)
• Humans
• Male
• Non-alcoholic Fatty Liver Disease (drug therapy, metabolism)
• Oxidative Stress (drug effects)
• Phenylethyl Alcohol (administration & dosage, analogs & derivatives, pharmacology)
• Protein Carbonylation (drug effects)
• Treatment Outcome
• Vitamin E (administration & dosage, pharmacology)